Immunoprecise Antibodies Ltd (IPA) — Free Cash Flow Generation Index

Latest as of October 2020: -0.62x

Immunoprecise Antibodies Ltd (IPA) has a Free Cash Flow Generation Index of -0.62x as of October 2020. Free cash flow of $-274.98K represents -1% of operating cash flow ($440.23K). Explore IPA capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

-0.62x
Free Cash Flow / Operating CF

Free Cash Flow

$-274.98K
USD

Operating Cash Flow

$440.23K
USD

Capital Expenditures

$715.21K
USD

Immunoprecise Antibodies Ltd Free Cash Flow Generation Index (2016–2016)

Historical FCF Generation Index trend for Immunoprecise Antibodies Ltd across 1 annual periods. For the full cash flow conversion analysis, see Immunoprecise Antibodies Ltd operating cash flow efficiency.

Annual Free Cash Flow Generation for Immunoprecise Antibodies Ltd (2016–2016)

Year-by-year Free Cash Flow Generation Index for Immunoprecise Antibodies Ltd. Check total reinvestment intensity of Immunoprecise Antibodies Ltd to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2016 0.94x $266.61K $284.09K $17.48K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).